BIT’s 4th Annual Congress and Exposition of

Molecular Diagnostics (CEMD):

Overcome Misinterpretation of Symptoms

Beijing, China; September 22–24, 2011

Some of the most world’s leading experts in molecular diagnostics will participate in this international scientific conference.

Lecturer:

Dr. Serge Jurasunas

Title:

Clinical application of molecular markers, diagnostics in cancer and targeting therapies – case studies

1. Four years ago, we started to profile molecular markers genes for cancer patients and at the beginning with the oncogene tumor suppressor gene P53, whose critical role is evident by the fact that it is mutated in approximately 50% to 70% of all human cancer. P53 mutation represents a major causative factor in the development and progression of cancer and it contributes to tumor resistance to chemotherapy drugs.

The P53 tumor suppressor assay is completed with a battery of protein markers as BCL2, survivin (overexpressed in most breast cancer, BAX – inhibit in 70% of breast cancer), and P21 as novel cancer markers and for prognostic value. Not to be surprise most breast cancer demonstrates mutant P53 and other cases low level of P53 protein. Patients who are not responding to chemotherapy regimen showed additionally overexpressed BCL2 or survivin gene expression or both.

Survivin is virtually absent from normal breast tissues but present at very high levels in malignant breast cancer and may contribute to the development of breast cancer and predictor of poor prognostic.

2. P53-based anticancer therapies: restoring P53 function remain a main goal and an attractive target in oncology since it will improve the chemotherapy effectiveness and protect normal tissue from the detrimental toxic effects of antineoplasic drugs and to improve both survival and quality of life for cancer patients. Additionally molecular marker tests can predict early breast cancer or disease recurrence. The second objective is to normalize BCL2, survivin, and P21 gene expression.

We developed a strategy called the PSJ53 therapy made from natural compounds that have demonstrated efficiency to target mutant P53 with cancer patients treated in our clinic.

Clinical cases to be presented

Biography

Serge Jurasunas, a specialist in integrative medicine and cancer therapy, graduated both in naturopathic medicine (Canada 1969) and homeopathic medicine (South Africa 1975). His interests in nutrition, oxidative stress, and nontoxic approaches to cancer have given him the opportunity to become a well-regarded private researcher. Over the years, he has become acquainted with medical microscopy and oxidative stress. In recent years he has become more interested in targeting the oncogene P53 tumor suppressor gene, developed a therapy (PSJ53 therapy), and had some important success. He is now well experienced in reversing mutant P53 and restoring a normal wild type function.

The first results of case studies have been published in the US and Germany.

Dr. Jurasunas was appointed professor at Capital University of Integrative Medicine in Washington, D.C., in 1996. In 2006 he delivered a three-hour seminar on new avenues for treatment in oncology at Vilnius University (Lithuania) Faculty of Medicine. Over his career, he has received many awards and distinctions, including the Grand Gold Academic Collar of Scientific Merit from the International Accademia Di Pontzen (Italy) and the Dag Hammarskjöld Award for Medicine, and he is a member of the American Academy of Anti-Aging Medicine, the New York Academy of Sciences, and the Society of Integrative Oncology. Dr. Jurasunas’s work in the field of integrative medicine is known all over the world and published in 14 languages.